Upload Records Snowball Search Search OpenAlex
About the database ScholarIQanswers from OpenAlex
Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study
PaperCitations, authors & open-access status
Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study is a paper indexed in ScholarIQ from OpenAlex. ScholarIQ records 1,712 citations, 2018 year and green oa status.
1,712
Citations
2018
Year
green
OA Status